Photo by on Unsplash

Nine months after the release of the iPrognosis application, the project partners circulated a short questionnaire with the aim to collect feedback from app users and guide the next project developments. This article presents a summary of the user evaluation findings.

Since the release in April 2017, 749 Europeans downloaded the iPrognosis mobile application and provided consent to participate in the GData collection study. This study aims at extracting behavioral features indicative of Parkinson’s and training the algorithms behind the app that will eventually be able to identify symptoms related to the disease.
More information about the GData study


Very positive evaluation by current users

The first evaluation of the iPrognosis mobile app gave supportive findings. The good performance results echo the results of the technical evaluation performed internally by  project partners. The app is fully functional and does not alter the normal operation of the respondents’ smartphones.

The evaluation also permitted to demonstrate the user-friendly character of the app. These results are supported by the little assistance needed by respondents to both set up or use the app. This first user acceptance evaluation evidenced a relatively high intention to use a Parkinson’s disease early detection app by actual users of iPrognosis who considered the mobile app as a useful tool to improve medical research around PD early detection.


But more awareness-raising needed for wide adoption

This evaluation gives project partners important signals for further development of the project to ensure the accessibility and wide adoption of the app by both users and their healthcare professionals. Thus participants’ responses in some countries highlighted the importance to keep informing about how privacy is protected and to raise the awareness of healthcare professionals to ensure their inclusion in these novel processes for early PD detection.

According to evaluation results, the use of daily technologies for medical purposes seems to be more accepted in Greece and the UK than in Germany and Portugal. Similarly, German respondents have been more hesitant regarding the capacity of the project to reassure them on data protection and to provide necessary guidance for 40+ to use and install the app.